R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics
7.6.2022 10:00:00 CEST | news aktuell GmbH | Pressemelding
Darmstadt, June 7, 2022 – R-Biopharm AG, a leading German biotechnology company operating on a global scale, announced the acquisition of AusDiagnostics. R-Biopharm is expanding its product portfolio with the addition of the Australian specialist and manufacturer of molecular biology multiplex diagnostics, extraction reagents, and laboratory automation equipment. The company is thereby unlocking new market segments in clinical diagnostics and continuing on its path of steady internationalization. “The existing and future molecular biology multiplex analysis platforms for syndrome testing from system supplier AusDiagnostics broadens our molecular biology expertise and perfectly complements our present clinical diagnostics portfolio,” states Christian Dreher, CEO of R-Biopharm. “The acquisition strengthens our position as a reliable partner for system solutions and offers our customers additional options for diagnostics.”
Upon its establishment in 2006, the Australian company introduced its patented Multiplex Tandem PCR (MT-PCR) on the market. The current technology allows the simultaneous detection of up to 24 pathogens or resistance genes from a single sample, thus shortening the lengthy test procedure in human and animal diagnostics as well as environmental, agricultural, and food analysis. The analysis platform is used in laboratories and hospitals throughout the world for detecting a broad range of diseases.
AusDiagnostics CEO Scott Gilroy said that the transaction marked an exciting new chapter for the company: “Both AusDiagnostics and R-Biopharm AG share the same commitment to innovation in the biotechnology space. This acquisition strengthens AusDiagnostics and will accelerate our global presence. We’ve experienced tremendous, industry-leading growth over the past two years, which has been underpinned by our broad suite of innovative products, talented team, and incredible, loyal customers. Joining the R-Biopharm group will allow us to further build on this and continue to deliver exceptional products and service for our Australian and international customers.”
AusDiagnostics currently has 92 employees with offices in New Zealand, the USA, and Great Britain. Its production facilities in Australia and Great Britain supply a steadily growing network of more than 25 distributors and partners around the world – from which R-Biopharm expects further synergy effects for production as well as international service and support in its clinical diagnostics line.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany’s leading biotechnology companies. It considers itself as a pioneer for health and quality of life. The company´s aspiration is to provide the highest possible precision, safety, clarity and certainty with excellent products and solutions – in prevention, therapy and healing. Research and development at R-Biopharm has developed agile processes in order to take on new challenges to accompany a steadily growing world population into a new health era with sustainable solutions.
As an internationally recognized leader, R-Biopharm stands for the development of excellent technologies, products and solutions in the fields of Clinical Diagnostics, Nutrition Care and Food and Feed Analytics. R-Biopharm is the global market leader for test systems in the field of allergen analysis. The biotechnology company is known for its products that are of high importance for human health. To this end, it unites development, production and sales under one roof and is successfully represented in more than 120 countries worldwide – through 28 subsidiaries and 120 distributors. Founded in 1988, the family-run company employs a total of around 1,300 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the “Sustainability Award” for sustainable and profitable growth. R-Biopharm is cultivating a value-oriented corporate culture and management and is family-run in the second generation. The Chairman of the Board of Directors is Christian Dreher.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: +49 61 51 - 81 02-538
Mobile: +49 160 - 55 273 60
Fax: +49 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Bilder
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Infomaniak launches a new sovereign, S3-compatible object storage service with predictable costs5.11.2026 12:07:40 CET | Press release
Geneva, 5 November 2026 – Infomaniak, a Swiss cloud service provider, is launching a new S3-compatible object storage service in its sovereign Public Cloud. Businesses and developers can use it to store backups, archives or AI data with the S3-compatible tools they already use. Files can be locked against any modification or deletion for a chosen period and, once the option is enabled, automatically copied to a second Infomaniak data centre in Switzerland. The service is billed on a pay-as-you-go basis, with 10 TB of outbound traffic included every month and no request fees. Data stays in Switzerland, under Swiss jurisdiction, with an independent provider. Protecting data against attacks and incidents Object storage is used to keep large volumes of files. A business can, for example, store its server backups, its archives or the images and videos for its website. A developer can keep application files or the training data for an AI model. Files are encrypted at rest and in transit, and
Donation Campaign by Michelangelo-Julius II.-Figur e. V. (€42 Million)5.11.2026 10:00:00 CET | Press release
Frankfurt am Main, November 2026. Modelled on the French initiative “100 euros - 1 Picasso”, the campaign “100 euros - 1 Michelangelo figure of the 16th century” offers one donor the chance to receive a wooden figure of Pope Julius II. The non-profit association Michelangelo-Julius II.-Figur e. V. considers this piece a rediscovered masterpiece by Michelangelo Buonarroti. CEZ scientific analysis dates the wood to around 1500, aligning directly with Michelangelo’s era. All proceeds will be divided 50:50 between the Nobel Peace Prize laureate Doctors Without Borders (Médecins Sans Frontières) and the association. A comprehensive account of the artwork is published on michelangelo-lost-masterpiece.com. The figure represents Pope Julius II; while the famous bronze monument in Bologna was destroyed, the association views this surviving wooden bozzetto as the sole preserved sculptural record and one of the rarest wooden works attributed to Michelangelo. Worldwide participation is strictly ca
Munich Arena breaks ground, marking a new era for live music in Europe30.10.2026 09:00:53 CET | Press release
20,000 capacity "Music first" venue: The Munich Arena will be Germany's first concert arena specifically designed for music and live entertainment. The combination of striking architecture, exceptional acoustics, excellent sightlines, premium hospitality and world-class production facilities for artists and promoters will make Munich Arena one of Europe’s leading live music venues. Economic impact of €355 million per year: Munich Arena will boost the economy and culture for Munich and Bavaria, a Deloitte study estimates the economic impact to be around €355 million per year when the venue is open. Countdown to the opening in 2029 has begun: Freising’s lord mayor Monika Schwind joined Marek Lieberberg, President Live Nation GSA, Tom Lynch, President Live Nation Venues, Lorenz Schmid, Managing Partner Munich Arena, and Bavarian Prime Minister Dr. Markus Söder to officially break ground on Munich Arena. A supporter of Munich’s Olympic concept and the Free State of Bavaria:. Munich Arena i
Flamingo-1: Germany’s First Space-Based SDA Telescope Delivers Commercial Space Surveillance and Tracking29.10.2026 10:39:13 CET | Press release
(Munich, Germany) – Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has entered routine operations with its Flamingo-1 satellite. The satellite operates at a high duty cycle, continuously monitoring space objects, scouting for threats from low Earth orbit (LEO) to geostationary Earth orbit (GEO). The space-based image data generated by Flamingo-1 is further processed by Vyoma into products, services and intelligence in high demand among the SDA community and Vyoma’s customers to better understand the space domain from both a safety and a security perspective. The information is delivered to the company’s customers through the Vyoma Services Platform. Flamingo-1 operates both in surveillance and in tracking mode. In surveillance mode, the satellite continuously screens a large volume of space, setting it apart from ground-based optical systems that are idle during the day or when obstructed by bad weather. This high volume of data is ideal for creatin
Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain28.10.2026 09:30:00 CET | Press release
Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.[i]
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom